Loading
A phase 2 trial of Lifileucel in melanoma and skin cancer, run by Iovance Biotherapeutics, Inc., active and no longer recruiting.
A Study of Lifileucel (Tumor-infiltrating Lymphocytes) in Adults With Advanced Melanoma is a phase 2 interventional study registered as NCT07288203 by Iovance Biotherapeutics, Inc., with 100 participants planned, started 2025-11-28 and due to reach its primary completion in 2032-12. Interventions recorded: Lifileucel. Conditions listed: Melanoma (Skin Cancer), Unresectable Melanoma, Metastatic Melanoma. No results are recorded here; the registry entry is the source.
The full inclusion and exclusion criteria are on the registry record. Read 2026-10-07. Recruiting overall does not mean a particular site is open; ask the study team.
ClinicalTrials.gov data courtesy of the US National Library of Medicine.
Shares Iovance Biotherapeutics, Lifileucel, TIL therapy, Advanced melanoma (unresectable stage III and stage IV).
Shares Iovance Biotherapeutics, Lifileucel, TIL therapy.
Shares Iovance Biotherapeutics, Advanced melanoma (unresectable stage III and stage IV), Melanoma.
Shares Iovance Biotherapeutics, Advanced melanoma (unresectable stage III and stage IV), Melanoma.
Shares Iovance Biotherapeutics, Advanced melanoma (unresectable stage III and stage IV), Melanoma.
Shares Lifileucel, TIL therapy, Advanced melanoma (unresectable stage III and stage IV), Melanoma.
Shares Lifileucel, TIL therapy, Melanoma.
Shares Iovance Biotherapeutics, Lifileucel, TIL therapy.
Every source this page cites, grouped by who published it. Grouping is read from the web address, not assigned by hand.
A source that has moved or gone is reported by the weekly link check. /audit/